<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid>9992025</pmcid><all-ids><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmid">36750534</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmc">9992025</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="publisher-id">4254</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="doi">10.1007/s11060-023-04254-1</article-id></all-ids><extracted-table><table-id>Tab1</table-id><table-label>Table 1</table-label><table-caption>Patient characteristics</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="Tab1"><label>Table 1</label><caption><p>Patient characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">All Glioma Patients (n = 121)</th><th align="left">Left-Sided Glioma (n = 65)</th><th align="left">Right-Sided Glioma (n = 56)</th><th align="left">p</th></tr></thead><tbody><tr><td align="left">Gender (male/female)</td><td align="left">73/48</td><td align="left">36/29</td><td align="left">37/19</td><td char="." align="char">0.23</td></tr><tr><td align="left">Age (years)</td><td align="left">52 (28–74)</td><td align="left">52 (28–74)</td><td align="left">52 (29–73)</td><td char="." align="char">0.88</td></tr><tr><td align="left">ECOG-PS (0/1–2)</td><td align="left">58/63</td><td align="left">34/31</td><td align="left">24/32</td><td char="." align="char">0.30</td></tr><tr><td align="left">Education (ISCED-Score)</td><td align="left">8 (3–10)</td><td align="left">8 (3–10)</td><td align="left">7 (3–10)</td><td char="." align="char">0.58</td></tr><tr><td align="left">Employment (no/yes)</td><td align="left">45/76</td><td align="left">23/42</td><td align="left">22/34</td><td char="." align="char">0.40</td></tr><tr><td align="left">Follow-up interval (months)</td><td align="left">14.4 (0.6–213.7)</td><td align="left">14.7 (0.6–190.9)</td><td align="left">13.5 (0.6–213.7)</td><td char="." align="char">0.69</td></tr><tr><td align="left">Presenting symptoms</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left"> Aphasia</td><td align="left">17</td><td align="left">15</td><td align="left">2</td><td char="." align="char"><italic>0.002</italic></td></tr><tr><td align="left"> Paresis</td><td align="left">29</td><td align="left">12</td><td align="left">17</td><td char="." align="char">0.13</td></tr><tr><td align="left"> Fatigue</td><td align="left">19</td><td align="left">8</td><td align="left">11</td><td char="." align="char">0.27</td></tr><tr><td align="left"> Vision</td><td align="left">12</td><td align="left">5</td><td align="left">7</td><td char="." align="char">0.38</td></tr><tr><td align="left"> Vertigo, confusion</td><td align="left">4</td><td align="left">2</td><td align="left">2</td><td char="." align="char">0.88</td></tr><tr><td align="left">Tumor type</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left"> GBM, IDH wildtype</td><td align="left">67</td><td align="left">31</td><td align="left">36</td><td char="." align="char">0.49</td></tr><tr><td align="left"> GBM, IDH mutant</td><td align="left">10</td><td align="left">7</td><td align="left">3</td><td char="." align="char">–</td></tr><tr><td align="left"> GBM, NOS</td><td align="left">4</td><td align="left">3</td><td align="left">1</td><td char="." align="char">–</td></tr><tr><td align="left"> AA, IDH wildtype</td><td align="left">5</td><td align="left">2</td><td align="left">3</td><td char="." align="char">–</td></tr><tr><td align="left"> AA, IDH mutant</td><td align="left">16</td><td align="left">9</td><td align="left">7</td><td char="." align="char">–</td></tr><tr><td align="left"> AA, NOS</td><td align="left">7</td><td align="left">5</td><td align="left">2</td><td char="." align="char">–</td></tr><tr><td align="left"> AOD, IDH-mut&amp;1p19q codel</td><td align="left">12</td><td align="left">8</td><td align="left">4</td><td char="." align="char">–</td></tr><tr><td align="left">Tumor location*</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left"> Frontal</td><td align="left">59</td><td align="left">31</td><td align="left">28</td><td char="." align="char">0.90</td></tr><tr><td align="left"> Parietal</td><td align="left">15</td><td align="left">7</td><td align="left">8</td><td char="." align="char">–</td></tr><tr><td align="left"> Temporal</td><td align="left">38</td><td align="left">22</td><td align="left">16</td><td char="." align="char">–</td></tr><tr><td align="left"> Occipital</td><td align="left">9</td><td align="left">5</td><td align="left">4</td><td char="." align="char">–</td></tr><tr><td align="left">Lesion volumes</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">–</td></tr><tr><td align="left"> Resection cavity (mL)</td><td align="left">9.3 (0–172.5)</td><td align="left">9.0 (0–161.5)</td><td align="left">9.6 (0–172.5)</td><td char="." align="char">0.88</td></tr><tr><td align="left"> FLAIR hyperintense (mL)</td><td align="left">53.4 (3.4–252.9)</td><td align="left">48.7 (3.4–252.9)</td><td align="left">56.2 (4.4–232.6)</td><td char="." align="char">0.062</td></tr><tr><td align="left"> T1 contrast enhancing (mL)</td><td align="left">5.4 (0–122.9)</td><td align="left">2.5 (0–88.0)</td><td align="left">8.1 (0–122.9)</td><td char="." align="char">0.13</td></tr><tr><td align="left"> FET-PET pathol. Uptake (mL)</td><td align="left">14.9 (0–227.8)</td><td align="left">8.2 (0–127.3)</td><td align="left">20.1 (0–227.8)</td><td char="." align="char">0.066</td></tr><tr><td align="left">Treatment (Number of Procedures)</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left"> Surgery# (1/2/3/4)</td><td align="left">101/17/2/1</td><td align="left">54/9/1/1</td><td align="left">47/8/1/0</td><td char="." align="char">0.83</td></tr><tr><td align="left"> Radiotherapy (0/1/2)</td><td align="left">7/100/14</td><td align="left">4/55/6</td><td align="left">3/45/8</td><td char="." align="char">0.43</td></tr><tr><td align="left"> Chemotherapy (0/1/2/3)</td><td align="left">10/91/16/4</td><td align="left">8/48/5/4</td><td align="left">2/43/11/0</td><td char="." align="char">0.15</td></tr><tr><td align="left">Corticosteroids (no/yes)</td><td align="left">91/30</td><td align="left">51/14</td><td align="left">40/16</td><td char="." align="char">0.25</td></tr><tr><td align="left">Anticonvulsants (no/yes)</td><td align="left">49/72</td><td align="left">27/38</td><td align="left">22/34</td><td char="." align="char">0.47</td></tr><tr><td align="left">FET pathol. Uptake (no/yes)</td><td align="left">63/58</td><td align="left">36/29</td><td align="left">27/29</td><td char="." align="char">0.27</td></tr></tbody></table><table-wrap-foot><p>Median (Range) unless otherwise stated; <italic>ECOG</italic>-<italic>PS</italic> eastern cooperative oncology group performance score; <italic>ISCED</italic> international standard classification of education (1997); <italic>GBM</italic> glioblastoma; <italic>NOS</italic> not otherwise specified; <italic>AA</italic> anaplastic astrocytoma; <italic>AOD</italic> anaplastic oligodendroglioma; <italic>IDH</italic> Isocitrate-Dehydrogenase; 1p19q <italic>codel</italic> 1p19q codeleted; <italic>FET</italic> O-(2-[18F]fluoroethyl)-L-tyrosine; *main lobe involved #including biopsy</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 1<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Patient characteristics</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">All Glioma Patients (n = 121)</th><th align="left">Left-Sided Glioma (n = 65)</th><th align="left">Right-Sided Glioma (n = 56)</th><th align="left">p</th></tr></thead><tbody><tr><td align="left">Gender (male/female)</td><td align="left">73/48</td><td align="left">36/29</td><td align="left">37/19</td><td char="." align="char">0.23</td></tr><tr><td align="left">Age (years)</td><td align="left">52 (28–74)</td><td align="left">52 (28–74)</td><td align="left">52 (29–73)</td><td char="." align="char">0.88</td></tr><tr><td align="left">ECOG-PS (0/1–2)</td><td align="left">58/63</td><td align="left">34/31</td><td align="left">24/32</td><td char="." align="char">0.30</td></tr><tr><td align="left">Education (ISCED-Score)</td><td align="left">8 (3–10)</td><td align="left">8 (3–10)</td><td align="left">7 (3–10)</td><td char="." align="char">0.58</td></tr><tr><td align="left">Employment (no/yes)</td><td align="left">45/76</td><td align="left">23/42</td><td align="left">22/34</td><td char="." align="char">0.40</td></tr><tr><td align="left">Follow-up interval (months)</td><td align="left">14.4 (0.6–213.7)</td><td align="left">14.7 (0.6–190.9)</td><td align="left">13.5 (0.6–213.7)</td><td char="." align="char">0.69</td></tr><tr><td align="left">Presenting symptoms</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left"> Aphasia</td><td align="left">17</td><td align="left">15</td><td align="left">2</td><td char="." align="char">0.002</td></tr><tr><td align="left"> Paresis</td><td align="left">29</td><td align="left">12</td><td align="left">17</td><td char="." align="char">0.13</td></tr><tr><td align="left"> Fatigue</td><td align="left">19</td><td align="left">8</td><td align="left">11</td><td char="." align="char">0.27</td></tr><tr><td align="left"> Vision</td><td align="left">12</td><td align="left">5</td><td align="left">7</td><td char="." align="char">0.38</td></tr><tr><td align="left"> Vertigo, confusion</td><td align="left">4</td><td align="left">2</td><td align="left">2</td><td char="." align="char">0.88</td></tr><tr><td align="left">Tumor type</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left"> GBM, IDH wildtype</td><td align="left">67</td><td align="left">31</td><td align="left">36</td><td char="." align="char">0.49</td></tr><tr><td align="left"> GBM, IDH mutant</td><td align="left">10</td><td align="left">7</td><td align="left">3</td><td char="." align="char">–</td></tr><tr><td align="left"> GBM, NOS</td><td align="left">4</td><td align="left">3</td><td align="left">1</td><td char="." align="char">–</td></tr><tr><td align="left"> AA, IDH wildtype</td><td align="left">5</td><td align="left">2</td><td align="left">3</td><td char="." align="char">–</td></tr><tr><td align="left"> AA, IDH mutant</td><td align="left">16</td><td align="left">9</td><td align="left">7</td><td char="." align="char">–</td></tr><tr><td align="left"> AA, NOS</td><td align="left">7</td><td align="left">5</td><td align="left">2</td><td char="." align="char">–</td></tr><tr><td align="left"> AOD, IDH-mut&amp;1p19q codel</td><td align="left">12</td><td align="left">8</td><td align="left">4</td><td char="." align="char">–</td></tr><tr><td align="left">Tumor location*</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left"> Frontal</td><td align="left">59</td><td align="left">31</td><td align="left">28</td><td char="." align="char">0.90</td></tr><tr><td align="left"> Parietal</td><td align="left">15</td><td align="left">7</td><td align="left">8</td><td char="." align="char">–</td></tr><tr><td align="left"> Temporal</td><td align="left">38</td><td align="left">22</td><td align="left">16</td><td char="." align="char">–</td></tr><tr><td align="left"> Occipital</td><td align="left">9</td><td align="left">5</td><td align="left">4</td><td char="." align="char">–</td></tr><tr><td align="left">Lesion volumes</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">–</td></tr><tr><td align="left"> Resection cavity (mL)</td><td align="left">9.3 (0–172.5)</td><td align="left">9.0 (0–161.5)</td><td align="left">9.6 (0–172.5)</td><td char="." align="char">0.88</td></tr><tr><td align="left"> FLAIR hyperintense (mL)</td><td align="left">53.4 (3.4–252.9)</td><td align="left">48.7 (3.4–252.9)</td><td align="left">56.2 (4.4–232.6)</td><td char="." align="char">0.062</td></tr><tr><td align="left"> T1 contrast enhancing (mL)</td><td align="left">5.4 (0–122.9)</td><td align="left">2.5 (0–88.0)</td><td align="left">8.1 (0–122.9)</td><td char="." align="char">0.13</td></tr><tr><td align="left"> FET-PET pathol. Uptake (mL)</td><td align="left">14.9 (0–227.8)</td><td align="left">8.2 (0–127.3)</td><td align="left">20.1 (0–227.8)</td><td char="." align="char">0.066</td></tr><tr><td align="left">Treatment (Number of Procedures)</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left"> Surgery# (1/2/3/4)</td><td align="left">101/17/2/1</td><td align="left">54/9/1/1</td><td align="left">47/8/1/0</td><td char="." align="char">0.83</td></tr><tr><td align="left"> Radiotherapy (0/1/2)</td><td align="left">7/100/14</td><td align="left">4/55/6</td><td align="left">3/45/8</td><td char="." align="char">0.43</td></tr><tr><td align="left"> Chemotherapy (0/1/2/3)</td><td align="left">10/91/16/4</td><td align="left">8/48/5/4</td><td align="left">2/43/11/0</td><td char="." align="char">0.15</td></tr><tr><td align="left">Corticosteroids (no/yes)</td><td align="left">91/30</td><td align="left">51/14</td><td align="left">40/16</td><td char="." align="char">0.25</td></tr><tr><td align="left">Anticonvulsants (no/yes)</td><td align="left">49/72</td><td align="left">27/38</td><td align="left">22/34</td><td char="." align="char">0.47</td></tr><tr><td align="left">FET pathol. Uptake (no/yes)</td><td align="left">63/58</td><td align="left">36/29</td><td align="left">27/29</td><td char="." align="char">0.27</td></tr></tbody></table></div>Median (Range) unless otherwise stated; ECOG-PS eastern cooperative oncology group performance score; ISCED international standard classification of education (1997); GBM glioblastoma; NOS not otherwise specified; AA anaplastic astrocytoma; AOD anaplastic oligodendroglioma; IDH Isocitrate-Dehydrogenase; 1p19q codel 1p19q codeleted; FET O-(2-[18F]fluoroethyl)-L-tyrosine; *main lobe involved #including biopsy</transformed-table></extracted-table></extracted-tables-set>